Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment
Frontiers in Bioscience-Landmark · 2024
DOI: 10.31083/j.fbl2910349 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Namdev Dhas und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India. Hauptthemen laut MEDLINE: Tumor Microenvironment, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 332 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The immune system and cancer cells interact intricately during the growth of tumors, and the dynamic interplay between immune activation and suppression greatly influences the cancer outcome. Natural killer cells (NK), cytotoxic T lymphocytes (CTLs) and Dendritic cells (DC), employ diverse mechanisms, to combat cancer. However, the challenges posed by factors such as chronic inflammation and the immunosuppressive tumor microenvironment (TME) often hinder immune cells' ability to detect and eliminate tumors accurately. Immunotherapy offers a promising approach, reprogramming the immune system to target and eliminating cancer cells while minimizing side effects, enhancing immune memory, and lowering the risk of metastasis and relapse compared to traditional treatments like radiation and surgery. Nanotechnology presents a potential solution by enabling safer, more efficient drug delivery through nanoparticles. These nanoengineered drugs can be tailored for controlled activation and release. Improving TME characters holds potential for enhancing personalized immunotherapy and addressing T cell availability issues within tumor sites, particularly when combined with existing therapies. This review discusses TMEs and the strategies to overcome immunosuppression in TME, and various immune cell-based strategies to improve antitumor response. It also focuses on the strategies for constructing microenvironment responsive nanoplatforms based upon the factors present at higher levels in TME like acidic pH, hypoxia facilitated by poor oxygen supply, higher expression of certain enzymes, and other factors such light, ultrasound and magnetic field. Combination immune therapies combined with immunotherapy include photodynamic therapy, photothermal therapy, chemotherapy, gene therapy and radiotherapy, revealing a high level of anticancer activity in comparison to a single therapy, enhancing immunogenicity, promoting therapeutic efficacy, and lowering metastasis. In conclusion, cancer immunotherapy is a potential technique to combat cancer cells and boost the immune system, hindering their growth and recurrence. In order to prevent cancer, it helps the immune system target cancer cells selectively and strengthens its long-term memory. Clinical trials are extending the application of immunotherapy and identifying strategies to improve the immune system tumor-fighting capabilities. Immunotherapy has enormous promise and gives hope for more successful cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.
- Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, 576104 Manipal, Karnataka, India.
- Department of Pharmaceutics, R. C. Patel Institute of Pharmaceutical Education and Research, 425405 Shirpur, Maharashtra, India.
- PSIT-Pranveer Singh Institute of Technology (Pharmacy), 209305 Kanpur, Uttar Pradesh, India.
- Faculty of Pharmacy, Sankalchand Patel University, 384315 Visnagar, Gujurat, India.
Zitieren
APA
Dhas, N., Kudarha, R., Kulkarni, S., Soman, S., Navti, P. D., Kulkarni, J., Roy, A. A., Colaco, V., Raychaudhuri, R., Gupta, A., Pardeshi, C., Bari, D., Tiwari, R., Patel, J., Moorkoth, S., & Mutalik, S. (2024). Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2910349
Vancouver
Dhas N, Kudarha R, Kulkarni S, Soman S, Navti PD, Kulkarni J, et al. Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2910349
BibTeX
@article{Dhas2024,
author = {Dhas, Namdev and Kudarha, Ritu and Kulkarni, Sanjay and Soman, Soji and Navti, Prerana D and Kulkarni, Jahnavi and Roy, Amrita Arup and Colaco, Viola and Raychaudhuri, Ruchira and Gupta, Ashutosh and Pardeshi, Chandrakantsing and Bari, Dipak and Tiwari, Ruchi and Patel, Jayvadan and Moorkoth, Sudheer and Mutalik, Srinivas},
title = {Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment},
journal = {Frontiers in Bioscience-Landmark},
year = {2024},
doi = {10.31083/j.fbl2910349}
}
EUVIMED